Maintenance Therapy Post-HSCT in High-risk Aggressive Lymphoma
Relapse after autologous hematopoietic stem cell transplantation (ASCT) is still challenging for high-risk aggressive lymphoma. This study was to investigate the efficacy and safety of maintenance therapy post-ASCT.
High-risk Aggressive Lymphoma After Auto-HSCT
DRUG: Maintenance therapy post-HSCT
Relapse rate, 2 years
Overall survival, 2 years|Treatment-related mortality, 2 years
Relapse after autologous hematopoietic stem cell transplantation (ASCT) is still challenging for high-risk aggressive lymphoma. This study was to investigate the efficacy and safety of maintenance therapy post-ASCT.